Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer cells in patients’ blood, research from the University of Michigan and the University of Kansas suggests.
Spinal cord injury (SCI) remains a major unmet medical challenge, often resulting in permanent paralysis and disability with no effective treatments. Now, researchers at University of California San Diego School of Medicine have harnessed bioinformatics to fast-track the discovery of a promising new drug for SCI.
Deep brain stimulation (DBS) is a surgical procedure that entails the delivery of high-frequency electrical impulses to specific regions of the brain, via surgically implanted electrodes.
The technology would allow battery-free, minimally invasive, scalable bioelectronic implants such as pacemakers, neuromodulators, and body process monitors.
Findings point to promising drug that restores neuron balance and may slow disease progression
FastWave Medical today announced new first-in-human and pre-clinical data for its Sola coronary laser intravascular lithotripsy (L-IVL) system.
In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin cancer, and identified two mutated tumor proteins, or neoantigens, that contain features of good candidates for a vaccine.
A new clinical tool may improve how physicians assess the severity of a painful and often debilitating skin disorder, according to a study recently published in JAMA Dermatology.
A team of researchers at Purdue University and Merck & Co. Inc., known as Merck Sharp & Dohme Corp. outside of the U.S. and Canada, has now introduced a new analytical tool that could help pharmaceutical companies boost vaccine production with rapid monitoring and analysis.
Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), have revolutionized cancer treatment. But while they’ve delivered impressive results against certain blood cancers, they’ve struggled to make an impact in solid tumors, such as those in the breast, lung, and prostate.